» Articles » PMID: 9137844

Possible Mechanisms of Valproate in Migraine Prophylaxis

Overview
Journal Cephalalgia
Specialties Neurology
Psychiatry
Date 1997 Apr 1
PMID 9137844
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Valproate has been shown to be an effective prophylactic treatment in migraine. Investigation of the mechanism of its antimigraine action is difficult due to the broad range of its biochemical effects and the complex nature of migraine pathophysiology. Valproate increases brain GABA levels and, in doing so, may suppress migraine-related events in the cortex, perivascular parasympathetics or trigeminal nucleus caudalis. There is experimental evidence that it suppresses neurogenic inflammation and directly attenuates nociceptive neurotransmission. In addition, valproate reportedly alters levels of excitatory and inhibitory neurotransmitters and exerts direct effects on neuronal membranes in vitro. Valproate's observed effect may ultimately result from a combination of actions at different loci.

Citing Articles

Efficacy of prophylactic sodium valproate in pediatric migraines: a systematic review of randomized clinical studies.

Askar G, Askar O, Altuhafy M, Nagi R, Khan J Transl Pediatr. 2025; 13(12):2254-2266.

PMID: 39823012 PMC: 11732630. DOI: 10.21037/tp-24-279.


Abdominal migraine with acute watery diarrhea and dehydration: Successful treatment with Valproic acid in a pediatric case.

Amin M, Manna R, Nahin S, Hawlader M Clin Case Rep. 2024; 12(3):e8703.

PMID: 38523821 PMC: 10957485. DOI: 10.1002/ccr3.8703.


Migraine Comorbidities.

Cuciureanu D, Bistriceanu C, Vulpoi G, Cuciureanu T, Antochi F, Roceanu A Life (Basel). 2024; 14(1).

PMID: 38255689 PMC: 10820535. DOI: 10.3390/life14010074.


Mode and site of action of therapies targeting CGRP signaling.

Labastida-Ramirez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D J Headache Pain. 2023; 24(1):125.

PMID: 37691118 PMC: 10494408. DOI: 10.1186/s10194-023-01644-8.


A 5-Year Study of Antiseizure Medications (ASMs) Monitoring in Patients with Neuropsychiatric Disorders in an Italian Clinical Center.

Biso L, Carli M, Kolachalam S, Monticelli G, Calabro P, Di Paolo A Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513857 PMC: 10383891. DOI: 10.3390/ph16070945.